Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
Metrics: PDF 4697 views | HTML 3977 views | ?
Annelies Gonnissen1, Sofie Isebaert1 and Karin Haustermans1,2
1 University of Leuven (KU Leuven), Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium
2 University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium
Annelies Gonnissen, email:
Keywords: Hedgehog pathway, GLI transcription factors, GANT61, DNA repair, apoptosis
Received: March 24, 2015 Accepted: May 13, 2015 Published: May 22, 2015
An essential role for Hedgehog (Hh) signaling in human cancer has been established beyond doubt. At present, targeting Hh signaling has mainly been investigated with SMO inhibitors. Unfortunately, resistance against currently used SMO inhibitors has already been observed in basal cell carcinoma (BCC) patients. Therefore, the use of Hh inhibitors targeting the signaling cascade more downstream of SMO could represent a more promising strategy. Furthermore, besides the classical canonical way of Hh signaling activation, non-canonical activation of the GLI transcription factors by multiple important signaling pathways (e.g. MAPK, PI3K, TGFβ) has also been described, pinpointing the importance of targeting the transcription factors GLI1/2. The most promising agent in this context is probably the GLI1/2 inhibitor GANT61 which has been investigated preclinically in numerous tumor types in the last few years. In this review, the emerging role of Hh signaling in cancer is critically evaluated focusing on the potential of targeting Hh signaling more downstream of SMO, i.e. at the level of the GLI transcription factors. Furthermore, the working mechanism and therapeutic potential of the most extensively studied GLI inhibitor in human cancer, i.e. GANT61, is discussed in detail. In conclusion, GANT61 appears to be highly effective against human cancer cells and in xenograft mouse models, targeting almost all of the classical hallmarks of cancer and could hence represent a promising treatment option for human cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.